Overview

Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer

Status:
Recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
This research is being performed to treat patient for head and neck cancer patients who have not received prior chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Bristol-Myers Squibb
Treatments:
Cisplatin
Docetaxel
Nivolumab